<DOC>
	<DOCNO>NCT03055988</DOCNO>
	<brief_summary>The objective study explore effect treatment tiotropium + olodaterol fix dose combination ( FDC ) compare fluticasone propionate + salmeterol FDC : - reversal leave ventricular diastolic dysfunction assess cardiac magnetic resonance ( CMR ) imaging , - measure arterial stiffness assess CMR pulse wave analysis ( PWA ) , - reduction hyperinflation assess body plethysmography - post dose spirometry .</brief_summary>
	<brief_title>Cardiovascular Function COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : All patient must sign informed consent consistent International Council Harmonisation Good Clinical Practice ( ICHGCP ) guideline prior participation trial , include medication washout restriction . All patient must diagnosis chronic obstructive pulmonary disease treat one longacting inhaled bronchodilator prior enrolment must meet follow spirometric criterion : Patients must stable airway obstruction postbronchodilator FEV1 &lt; 70 % predict normal calculated European Coal Steel Community ( ECSC ) formula , postbronchodilator FEV1/FVC &lt; 70 % Visit 1 Patients hyperinflation rest define Functional Residual capacity ( FRC ) &gt; 120 % predict , postbronchodilator reversibility great equal 7,5 % predict Visit 1 . Male female patient 40 75 year age ( inclusive ) day sign informed consent . Patients smoke history 10 pack year . Patients Modified Medical Research Council ( mMRC ) Dyspnoea score &gt; 1 Visit 1 . Patients must able perform technically acceptable pulmonary function test ( spirometry body plethysmography ) , Cardiac Magnetic Resonance ( CMR ) , brachial blood pressure measurement Pulse Wave Analysis ( PWA ) test study period require protocol . Patients must able inhale medication competent manner Respimat Accuhaler inhaler meter dose inhaler ( MDI ) . Exclusion criterion : Patients significant disease Chronic Obstructive Pulmonary Disease ( COPD ) . Patients clinically relevant abnormal baseline haematology , blood chemistry , creatinine . Patients diagnosis asthma . Patients COPD exacerbation 6 week prior screen ( Visit 1 ) patient experience COPD exacerbation respiratory tract infection washout phase prior randomisation . A history myocardial infarction , cerebrovascular event coronary artery intervention Coronary Artery Bypass Graft ( CABG ) within 1 year screening . Abnormal clinically significant 12lead Electrocardiogram ( ECG ) . Hospitalized heart failure within past year . Current severe heart failure ( New York Heart Association ( NYHA ) class IV . Ejection fraction &lt; = 40 % Cardiac Magnetic Resonance ( CMR ) baseline assessment . Patients systolic blood pressure &gt; 140mmHg and/or diastolic blood pressure &gt; 90mmHg Visit 1 . A diagnosis thyrotoxicosis . Known active tuberculosis , cardiac sarcoidosis . Any malignancy unless free disease least five year . A history cystic fibrosis . Clinically evident bronchiectasis . Patients severe emphysema require endobronchial intervention within 6 month prior screen . A history significant alcohol drug abuse . Patients undergone thoracotomy pulmonary resection . Patients treat oral ßadrenergics . Patients treat oral corticosteroid medication unstable dos ( i.e. , less four week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . Patients prescribed longterm home oxygen treatment . Patients complete pulmonary rehabilitation program six week prior screen visit patient currently pulmonary rehabilitation program . Patients take investigational drug within one month six half life ( whichever great ) prior screen visit . Patients know hypersensitivity ßadrenergics drug , anticholinergic drug , fluticasone propionate excipiens , Benzalkonium chloride ( BAC ) , Disodium edentate ( EDTA ) Lactose monohydrate ( contain milk protein ) component Respimat® Accuhaler® delivery system . Women pregnant , nursing , plan become pregnant trial . Women childbearing potential use highly effective method birth control . Patients previously enrol study currently enrol another study . Patient unable comply pulmonary medication restriction prior randomisation Patients pacemaker metal implant ( i.e . vascular clip stent , metal silver patient 's eye ) patient claustrophobia , due contraindication CMR .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>